2017 |
Dr. Yan Xu |
The impacts of EudraVigilance enhancement on signal detection - from the perspective of pharmaceutical industry *** |
|
|
2017 |
Andre Zernov |
Regulation of the pharmaceutical market in the EAEU, Russia and Ukraine: Similarities and differences |
|
|
2016 |
Silvia Balogh |
Extensions of indication in the European Union - a regulatory overview *** |
|
|
2016 |
Dr. Dagmar Behnke |
Implementing the new Pharmacovigilance legislation - challenges for the pharmaceutical industry *** |
|
|
2016 |
Dr. Mayte Bewersdorff |
Biosimilars in the U.S. - the long way to their first approval *** |
|
|
2016 |
Manuel Bilke |
EMA Clinical Data Transparency: A Critical Synopsis *** |
|
|
2016 |
Dr. Stefanie Blättermann |
Structured Product Labeling standard: A tool for IDMP implementation and electronic package leaflet creation? |
|
|
2016 |
Dr. Iris Bruchmüller |
Cannabis for medicinal and recreational purposes and new psychoactive substances – Critical review of recent legal initiatives in Germany *** |
|
|
2016 |
Dr. Sarah Büchner |
Coping with Drug Shortages through regulatory governance: Approaches and perspectives to a complex global challenge *** |
|
|
2016 |
Dr. Henrietta Dehmlow |
eCTD submissions - a global reality already? *** |
|
|
2016 |
Dr. Konstanze Eisfeld |
PRIority MEdicines (PRIME) – a scheme by the EMA to accelerate the development of medicines that target an unmet medical need |
|
|
2016 |
Annette Fries |
Regulatory Intelligence: How public information available in the internet can support a development strategy *** |
|
|
2016 |
Wolfgang Gulbins |
Between Standardisation and Flexibility - Defining Granularity of the eCTD Module 3.2.S for Different Types of Drug Substances in Europe *** |
|
|
2016 |
Tanja Hanikel |
Registration procedure for medical devices in the Russian Federation – under consideration of the new EEU regulations |
|
|
2016 |
Thomas Haupt |
Data and knowledge management optimization by introduction of a new Collaboration Tool (Microsoft SharePoint) in the Regulatory Affairs Department of a mid-sized pharmaceutical company |
|
|
2016 |
Dr. Niklas Jänich |
Paediatric Drug Development from a Labeling Perspective - A detailed view on the European Summary of Product Characteristics with an exemplary comparison to the US Prescribing Information *** |
|
|
2016 |
Helene Janzen |
Forced degradation studies - comparison between ICH, EMA, FDA and WHO guidelines and ANVISA's resolution RDC 53/2015 *** |
|
|
2016 |
Regina Kaiser |
Recent Developments on the EU-Regulatory Approach in mobile Health regarding mobile Health Apps which can be "medical Apps" or "non medical Apps" *** |
|
|
2016 |
Dr. Anja Kassner |
Harmonization of Regulated Product Submissions for Medical Devices - International Medical Device Regulators Forum Table of Content concept |
|
|
2016 |
Martina Kirsch |
Epigenetic Research bridges Clinical Research Gaps in Schizophrenia: Epigenetic Biomarker Development and Informed Consent Process Considerations in Clinical Trials |
|
|